title: Postoperative radioactive iodine administration for differentiated thyroid cancer patients.
abstract: OBJECTIVE
  Radioactive iodine (RAI) is administered postoperatively to the majority of thyroid cancer patients. No available study has demonstrated any benefit in low-risk patients.
  
  
  RESULTS
  RAI should be used selectively in low and intermediate-risk patients, based on the surgical and pathological reports and on postoperative serum thyroglobulin level and neck ultrasonography. When used, a low activity (30 mCi) is administered following recombinant human thyrotropin stimulation. High-risk patients are treated with a high activity of RAI (100 mCi or more).
  
  
  CONCLUSIONS
  RAI is not administered in many low-risk patients who can be reliably followed up with serum thyroglobulin determination on L-thyroxine treatment and neck ultrasonography. RAI may be administered in case of abnormality, and this delay will not reduce the chance of cure.
authors.affiliation: Gustave Roussy, University Paris Sud, Villejuif, Paris, France.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Lepoutre-Lussey
authors.forename: Désirée
authors.initials: D
authors.lastname: Deandreis
authors.forename: Sophie
authors.initials: S
authors.lastname: Leboulleux
authors.forename: Martin
authors.initials: M
authors.lastname: Schlumberger
mesh_terms: D017115:Catheter Ablation / Q000379:methods*; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage*; D018579:Patient Selection; D011182:Postoperative Care / Q000379:methods*; D017410:Practice Guidelines as Topic; D019275:Radiopharmaceuticals / Q000008:administration & dosage*; D013954:Thyroglobulin / Q000097:blood*; D013964:Thyroid Neoplasms / Q000601:surgery*; D013965:Thyroidectomy / Q000379:methods*; D013972:Thyrotropin / Q000097:blood; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D013972:Thyrotropin; D013954:Thyroglobulin